[{"data":1,"prerenderedAt":185},["ShallowReactive",2],{"drug-semaglutide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":73,"warnings":84,"renal":92,"monitoring":93,"interactions":94,"review":95,"examples":98,"atc":99,"iran":101,"links":117,"populations":138,"usApproval":180},"semaglutide",1,{"fa":7,"en":8},"سماگلوتاید (تزریقی هفتگی)","Semaglutide (weekly injection)","alimentary-metabolism",{"fa":11,"en":12},"آگونیست گیرنده GLP-1","GLP-1 receptor agonist",[14],{"name":15,"market":16},"Ozempic","US",[18,19,20],"ozempic","اوزمپیک","سماگلوتاید",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"pen","injection","sc","Pen 0.25\u002F0.5 mg, 1 mg or 2 mg per dose (0.68, 1.34 or 2.68 mg\u002FmL)",{"amount":5,"unit":28,"perUnit":29},"mg","application",[16],[32],{"source":33,"section":34},"fda-ozempic","3",[36,56],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":51},"t2d","type-2-diabetes",{"fa":40,"en":41},"دیابت نوع ۲ — هفته‌ای یک بار: ۰٫۲۵ mg × ۴ هفته، سپس ۰٫۵ mg","Type 2 diabetes — once weekly: 0.25 mg × 4 weeks, then 0.5 mg",{"minAge":43},{"value":44,"unit":45},18,"year","notCalculated",{"reason":48},{"fa":49,"en":50},"هفته‌ای یک بار زیرجلدی (نه روزانه). ۴ هفته ۰٫۲۵ mg (فقط برای تحمل)، سپس ۰٫۵ mg. در صورت نیاز پس از دست‌کم ۴ هفته ۱ mg و سپس ۲ mg؛ حداکثر ۲ mg در هفته.","Once WEEKLY subcutaneous (not daily). 0.25 mg for 4 weeks (tolerability only), then 0.5 mg. If needed after at least 4 weeks go to 1 mg, then 2 mg; max 2 mg weekly.",[52,54],{"source":33,"section":53},"2.2",{"source":33,"section":55},"2.1",{"id":57,"disease":57,"label":58,"population":61,"type":46,"unit":28,"dose":64,"refs":68},"obesity",{"fa":59,"en":60},"چاقی (Wegovy) — هفته‌ای یک بار: ۰٫۲۵ → ۰٫۵ → ۱ → ۱٫۷ → نگهدارنده ۲٫۴ mg","Obesity (Wegovy) — weekly: 0.25 → 0.5 → 1 → 1.7 → maintenance 2.4 mg",{"minAge":62},{"value":63,"unit":45},12,{"reason":65},{"fa":66,"en":67},"هفته‌ای یک بار زیرجلدی (نه روزانه): هفته ۱ تا ۴ ← ۰٫۲۵ mg؛ ۵ تا ۸ ← ۰٫۵؛ ۹ تا ۱۲ ← ۱؛ ۱۳ تا ۱۶ ← ۱٫۷؛ از هفته ۱۷ نگهدارنده ۲٫۴ mg (یا ۱٫۷). بزرگسال با تحمل ۲٫۴ mg تا ۴ هفته: حداکثر ۷٫۲ mg. همراه رژیم کم‌کالری و فعالیت.","Once WEEKLY SC (not daily): weeks 1–4 → 0.25 mg; 5–8 → 0.5; 9–12 → 1; 13–16 → 1.7; from week 17 maintenance 2.4 mg (or 1.7). Adults tolerating 2.4 mg for 4 weeks: up to 7.2 mg. With a reduced-calorie diet and activity.",[69,72],{"source":70,"section":71},"fda-wegovy","2.2, Table 1",{"source":70,"section":53},[74],{"id":75,"severity":76,"text":77,"refs":80},"mtc","block",{"fa":78,"en":79},"سابقه شخصی یا خانوادگی کارسینوم مدولاری تیروئید یا MEN 2؛ حساسیت جدی.","Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity.",[81,83],{"source":33,"section":82},"4",{"source":70,"section":82},[85],{"text":86,"refs":89},{"fa":87,"en":88},"هشدار جعبه‌ای: تومور سلول C تیروئید در جوندگان؛ در سابقه MTC یا MEN 2 ممنوع.","Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history.",[90],{"source":33,"section":91},"Boxed Warning",[],[],[],{"status":96,"reviewer":97,"date":97},"unverified",null,[],[100],"A10BJ06",{"status":102,"forms":103,"refs":112},"registered",[104,108],{"code":105,"en":106,"fa":107},"53482","SEMAGLUTIDE INJECTION, SOLUTION PARENTERAL 4 mg\u002F3 mL","محلول تزریقی سماگلوتاید ۴ میلی‌گرم \u002F ۳ میلی‌لیتر",{"code":109,"en":110,"fa":111},"53491","SEMAGLUTIDE INJECTION, SOLUTION PARENTERAL 8 mg\u002F3 mL","محلول تزریقی سماگلوتاید ۸ میلی‌گرم \u002F ۳ میلی‌لیتر",[113],{"source":114,"section":115,"url":116},"darooyab-generic","G-5532\u002FSemaglutide","https:\u002F\u002Fwww.darooyab.ir\u002FG-5532\u002FSemaglutide",[118,122,126,130,133,136],{"kind":119,"url":120,"label":121},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=209637","NDA209637",{"kind":123,"url":124,"label":125},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","FDA Ozempic",{"kind":127,"url":128,"label":129},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa619057.html","Semaglutide",{"kind":127,"url":131,"label":132},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618008.html","Semaglutide Injection",{"kind":134,"url":135,"label":100},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BJ06",{"kind":137,"url":116,"label":129},"darooyab",{"pregnancy":139,"lactation":148,"pediatric":156,"geriatric":164,"reproductive":172},{"level":140,"text":141,"quote":144,"refs":145},"caution",{"fa":142,"en":143},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.",[146],{"source":33,"section":147},"8.1",{"level":140,"text":149,"quote":152,"refs":153},{"fa":150,"en":151},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.",[154],{"source":33,"section":155},"8.2",{"level":140,"text":157,"quote":160,"refs":161},{"fa":158,"en":159},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and efficacy of OZEMPIC have not been established in pediatric patients.",[162],{"source":33,"section":163},"8.4",{"level":140,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC-treated patients were 65 years of age and over and 102 OZEMPIC-treated patients (3.2%) patients were 75 years of age and over.",[170],{"source":33,"section":171},"8.5",{"level":140,"text":173,"quote":176,"refs":177},{"fa":174,"en":175},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide [see Use in Specific Populations ( 8.1 )] .",[178],{"source":33,"section":179},"8.3",{"kind":181,"refs":182,"id":121},"NDA",[183],{"source":33,"section":184},"SPL approval \u002F marketing category",1792191867591]